A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer. [electronic resource]
Producer: 20201112Description: 16902 p. digitalISSN:- 2045-2322
- Animals
- Antineoplastic Agents, Immunological -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Cytoreduction Surgical Procedures -- methods
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Mice
- Mice, Inbred DBA
- Neoplasm, Residual
- Nivolumab -- therapeutic use
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Retrospective Studies
- Treatment Outcome
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.